Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Cytosorbents Crp(CTSO)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CTSO
09/28/2026: CTSO (1-star) is currently NOT-A-BUY. Pass it for now.
Cytosorbents is a medical technology company focused on blood purification, with its primary product, CytoSorb, used to remove inflammatory mediators in critical care settings. The company's main strength lies in its specialized hemadsorption technology, which has achieved a foothold in European markets. Its long-term investment story centers on potential US regulatory approval, which could significantly expand its market access. However, investors must weigh this against financial risks, including a lack of profitability and reliance on a narrow product portfolio. The stock may best suit growth-oriented investors with a high tolerance for risk, while market participants should closely monitor clinical trial updates and FDA engagement.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The growth narrative is highly dependent on binary outcomes like FDA approvals. |
| Momentum investor | Mixed fit | The stock often exhibits high volatility surrounding clinical trial updates. |
| Value investor | Weak fit | The company is not currently profitable, making traditional valuation metrics difficult to apply. |
| Dividend investor | Weak fit | The company does not pay dividends. |
| Low-risk investor | Weak fit | High clinical and execution risks lead to significant price volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks are sensitive to news, causing rapid price swings. |
| Valuation risk | Medium / high | Lack of profitability makes the stock price highly sensitive to future growth assumptions. |
| Competition risk (Major MedTech) | Medium / high | Larger players can exert pricing pressure or bundle competing technologies. |
| Business quality | Medium | The firm relies on a single technology platform which limits diversification. |
| Dividend income | Low / none | Investors should not expect income from this investment. |
| Execution risk | High | Success depends on complex regulatory pathways and hospital adoption cycles. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -73.79% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 12.67M USD | Price to earnings Ratio - | 1Y Target Price 47.5 |
Price to earnings Ratio - | 1Y Target Price 47.5 | ||
Volume (30-day avg) 20.6K shares | Beta 1.34 | 52 Weeks Range 3.94 - 20.40 | Updated Date 09/28/2026 |
52 Weeks Range 3.94 - 20.40 | Updated Date 09/28/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.32 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Critical Care | Sales of the CytoSorb hemadsorption cartridge. | The company makes money by selling specialized filters used in hospital intensive care units. |
| Geography: Europe | Primary revenue generation region for current operations. | Most current sales occur in European hospitals where the device is currently approved. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 7.2 | Enterprise Value 40.48M | Price to Sales(TTM) 0.34 |
Enterprise Value 40.48M | Price to Sales(TTM) 0.34 | ||
Enterprise Value to Revenue 1.09 | Enterprise Value to EBITDA -1.92 | Shares Outstanding 3.15M | Shares Floating 2.68M |
Shares Outstanding 3.15M | Shares Floating 2.68M | ||
Percent Insiders 15.99 | Percent Institutions 25.78 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Cytosorbents Crp
Exchange NASDAQ | Headquarters Princeton, NJ, United States | ||
IPO Launch date 2013-11-07 | CEO & Director Dr. Phillip P. Chan M.D., Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 129 | Website https://www.cytosorbents.com |
Full time employees 129 | Website https://www.cytosorbents.com | ||
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.